Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Naurex, Inc, an affiliate of Allergan plc
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of lead-in study
Adequate therapeutic benefit in the lead-in study to justify continuation of treatment with rapastinel in the judgement of the investigator
You may not be if
Suicide risk, as determined by meeting any of the following criteria:
1. A suicide attempt within the past year
2. Significant risk, as judged by the investigator, based on the psychiatric interview or information collected in the Columbia- Suicide Severity Rating Scale (C-SSRS) at any visit in the lead-in study
3. Montgomery-Asberg Depression Rating Scale (MADRS) Item 10 score ≥ 5 at any visit during participation in the lead-in study where MADRS was conducted.
At imminent risk of injuring self or others or causing significant damage to property, as judged by the investigator
Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during participation
Females of childbearing potential and male partners of females of childbearing potential, not using a reliable means of contraception
Clareo Health | Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
